全身放疗可治愈淋巴瘤：对其他恶性肿瘤而言是一种范例？
Systemic radiotherapy can cure lymphoma: a paradigm for other malignancies?
作者信息
DeNardo Gerald L, DeNardo Sally J, Balhorn Rod
机构信息
Department of Internal Medicine, University of California, Davis, Sacramento, CA 95816, USA.
出版信息
Cancer Biother Radiopharm. 2008 Aug;23(4):383-97. doi: 10.1089/cbr.2007.0523-U.
The cytocidal potency of a molecule can be augmented by conjugating a radionuclide for molecular targeted radionuclide therapy (MTRT) for cancer. Radioimmunotherapy (RIT) should be incorporated into the management of patients with B-cell non-Hodgkin's lymphoma (NHL) soon after the patients have proven incurable. Better drugs, strategies, and combinations with other drugs seem certain to make RIT integral to the management of patients with NHL and likely to lead to a cure of the currently incurable NHL. These improved drugs, strategies, and combinations thereof also offer opportunities for RIT to become part of the management of solid malignancies, including epithelial cancers. Smaller radionuclide carriers, such as those used for pretargeted strategies, provide dose intensification. The potential of pretargeted RIT to improve patient outcomes is striking.
通过结合用于癌症分子靶向放射性核素治疗（MTRT）的放射性核素，可以增强分子的杀细胞效力。在患者被证明无法治愈后，应尽快将放射免疫疗法（RIT）纳入B细胞非霍奇金淋巴瘤（NHL）患者的治疗中。更好的药物、策略以及与其他药物的联合使用似乎肯定会使RIT成为NHL患者治疗中不可或缺的一部分，并有可能治愈目前无法治愈的NHL。这些改进的药物、策略及其组合也为RIT成为包括上皮癌在内的实体恶性肿瘤治疗的一部分提供了机会。较小的放射性核素载体，如用于预靶向策略的载体，可实现剂量强化。预靶向RIT改善患者预后的潜力十分显著。
Zotero 插件